Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
3.860
+0.190 (5.18%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Lantern Pharma Employees
Lantern Pharma had 16 employees as of December 31, 2025. The number of employees decreased by 8 or -33.33% compared to the previous year.
Employees
16
Change (1Y)
-8
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$994,489
Market Cap
49.25M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 118 |
| aTyr Pharma | 60 |
| Mereo BioPharma Group | 39 |
| PDS Biotechnology | 21 |
| Veru Inc. | 20 |
| Instil Bio | 17 |
| CervoMed | 15 |
| Eloxx Pharmaceuticals | 10 |
LTRN News
- 15 days ago - Lantern Pharma files to sell 2.24M shares of common stock for holders - TheFly
- 16 days ago - Lantern Pharma Registration statement: Registration filing - Filings
- 26 days ago - Lantern Pharma reports data, updates from Phase 2 Harmonic trial on LP-300 - TheFly
- 26 days ago - Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer - Business Wire
- 5 weeks ago - Lantern receives successful response to Type C meeting from FDA on LP-300 - TheFly
- 5 weeks ago - Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC - Business Wire
- 6 weeks ago - Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates - Business Wire
- 6 weeks ago - Lantern Pharma Earnings release: Q1 2026 - Filings